Immuneering (IMRX) 12th Annual Cantor Fitzgerald Global Healthcare Conference summary

Strategic approach and technology

• Focuses on both attacking tumors and protecting patients to improve survival and quality of life.

• Developed Deep Cyclic Inhibition to decouple side effects from drug activity, enhancing tolerability.

• Technology enables blocking cancer pathways while allowing healthy cells to recover, reducing toxicity.

Atebimetinib program and differentiation

• Atebimetinib is a novel MEK inhibitor designed for broader use in BRAF and RAS mutant cancers.

• Demonstrates superior tolerability and efficacy compared to first-generation MEK inhibitors.

• Circulating tumor DNA data show fewer acquired alterations in the MAPK pathway, suggesting durable tumor control.

• Tumors treated with atebimetinib may develop less aggressive genetics post-treatment.

Clinical data and outcomes

• Phase II data in first-line pancreatic cancer show 17.3 months median overall survival, nearly double standard chemotherapy.

• 60% of patients proceeded to second-line therapy, compared to 40% in historical controls.

• 84% of evaluable patients were weight stable or gained weight at three months, addressing cancer cachexia.

• Patient baseline characteristics were older and had more adverse prognostic factors than historical controls.